Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kontinuum af pleje hos indlagte patienter med opioidbrugsforstyrrelse og smitsomme komplikationer fra stofbrug (CHOICE-STAR)

5. november 2026 opdateret af: Elana Rosenthal

Kontinuum af pleje hos hospitalsindlagte patienter med opioidbrugsforstyrrelse og infektiøse komplikationer af stofbrug - NavSTAR, behandling som sædvanlig, afhængighed/ID integreret klinik for at forhindre infektionsrelateret genindlæggelse

This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.

Studieoversigt

Detaljeret beskrivelse

This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.

(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.

The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.

Participants will be followed for 12 months.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

304

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20052
        • Rekruttering
        • George Washington University
        • Underforsker:
          • Irene Kuo, MD
        • Kontakt:
        • Ledende efterforsker:
          • Jill Catalanotti, MD
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University
        • Ledende efterforsker:
          • Joseph Carpenter, MD
        • Kontakt:
        • Underforsker:
          • Alina Steck, MD
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland Baltimore
        • Underforsker:
          • Edward Traver, MD
        • Ledende efterforsker:
          • Elana Rosenthal, MD
        • Underforsker:
          • Sarah Kattakuzhy, MD
        • Kontakt:
    • West Virginia
      • Morgantown, West Virginia, Forenede Stater, 26506
        • Rekruttering
        • West Virginia University
        • Kontakt:
        • Ledende efterforsker:
          • Rebecca Reece, MD
        • Underforsker:
          • Clinton Cooper, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
  3. Injection opioid or stimulant use in past 90 days - per patient self-report
  4. Active suspected or confirmed qualifying infection (see list) at time of admission.

Qualifying infections:

  • Non-vertebral osteomyelitis
  • Vertebral osteomyelitis or discitis
  • Epidural, subdural, or extradural abscess
  • Intracranial or intraspinal abscess
  • Native joint septic arthritis
  • Prosthetic joint septic arthritis
  • Blood stream infection (bacterial or fungal)
  • Native valve Endocarditis
  • Prosthetic valve endocarditis
  • Cardiac Implantable electronic device infection
  • Infectious pseudoaneurysm and aneurysm
  • Infected vascular graft
  • Septic venous thrombosis
  • Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
  • Infected skin ulcer
  • Orthopedic hardware infection
  • Muscle abscess/myositis
  • Central nervous system infection (bacterial or fungal)
  • Bacterial or fungal ophthalmologic infection
  • Other abscess
  • Pulmonary septic emboli
  • Other acute bacterial or fungal infection deemed appropriate by site study team

Exclusion Criteria:

  • 1. Infection due to a cause other than injection drug use, per determination of a site PI.

    2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.

    3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Treatment As Usual

Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital

Eksperimentel: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)

The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers.

Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Infection Rehospitalization
Tidsramme: 6 months after discharge for index hospitalization

New hospitalization due to infection following discharge for index hospitalization

6 months after discharge for index hospitalization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to first infection related readmission
Tidsramme: 12 months after discharge for index hospitalization

Time to first infection related readmission

12 months after discharge for index hospitalization
Reason for infection related readmission
Tidsramme: 12 months after discharge for index hospitalization

Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection)

12 months after discharge for index hospitalization
Hospital services utilization
Tidsramme: 12 months after discharge for index hospitalization

ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause)

12 months after discharge for index hospitalization
Mortality
Tidsramme: 12 months after discharge for index hospitalization

Death (Binary, time to death, cause of death)

12 months after discharge for index hospitalization
Index infection
Tidsramme: 3 months after discharge for index hospitalization

Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer)

3 months after discharge for index hospitalization
Other Infections
Tidsramme: 12 months after discharge for index hospitalization

HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days)

12 months after discharge for index hospitalization
Skin and soft tissue wounds
Tidsramme: 12 months after discharge for index hospitalization

Present (binary) Number (count) Per wound Size Location on body Duration (continuous)

12 months after discharge for index hospitalization
New infections not requiring hospitalization
Tidsramme: 12 months after discharge for index hospitalization
  • Present (binary)
  • Number (count)
12 months after discharge for index hospitalization
Outpatient linkage and retention
Tidsramme: 12 months after discharge for index hospitalization
  • Infectious Diseases Clinic (binary, time to linkage, count)
  • Medication for OUD Treatment (binary, time to linkage, count)
  • Non-medication based OUD Treatment (binary, time to linkage, count)
12 months after discharge for index hospitalization
Medication for Opioid Use (MOUD)
Tidsramme: 12 months after discharge for index hospitalization
  • On treatment (binary)
  • MOUD type
  • MOUD Dose
  • MOUD Dose adequacy
  • MOUD Source of medication
  • MOUD Location type
  • MOUD Co-location with other services
  • Reasons for no MOUD (descriptive)
12 months after discharge for index hospitalization
Medication for stimulant use (MStUD)
Tidsramme: 12 months after discharge for index hospitalization
  • On treatment (binary) MStUD type
  • MStUD Dose
  • MStUD Dose adequacy
  • MStUD Source of medication
  • MStUD Location type
  • MStUD Co-location with other services
  • Reasons for no MStUD (descriptive)
12 months after discharge for index hospitalization
Substance Use-Opioid
Tidsramme: 12 months after discharge for index hospitalization

Ongoing opioid (binary, mode)

  • Opioid use frequency
  • Mode of opioid use
  • Opioid craving
  • Other drug use (binary, mode)
  • Other drug use frequency
  • IDU (binary, frequency, mode (IM, IV, skin, other), location, syringe reuse, ssp engagement).
  • Severity (DAST)
  • Overdose (binary, count)
  • Tobacco use
  • UDS (binary - presence of opioids, )
12 months after discharge for index hospitalization
Substance Use - Stimulant
Tidsramme: 12 months after discharge for index hospitalization

Ongoing stimulant use (binary, mode)

  • Stimulant use frequency
  • Mode of stimulant use
  • Cocaine craving
  • Methamphetamine craving
  • Other drug use (binary, mode)
  • Other drug use frequency
  • IDU (binary, frequency, mode (IM, IV, skin, other), location, syringe reuse, ssp engagement).
  • Severity (DAST)
  • Overdose (binary, count)
  • Tobacco use
  • UDS (binary - presence of cocaine, amphetamines, other)
12 months after discharge for index hospitalization
Cost Effectiveness
Tidsramme: 12 months after discharge for index hospitalization

• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained

12 months after discharge for index hospitalization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Elana Rosenthal, MD, University of Maryland, Baltimore

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2024

Primær færdiggørelse (Anslået)

30. juli 2027

Studieafslutning (Anslået)

30. december 2027

Datoer for studieregistrering

Først indsendt

8. juli 2024

Først indsendt, der opfyldte QC-kriterier

15. juli 2024

Først opslået (Faktiske)

22. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner